Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1800 2
1887 1
1924 1
1941 1
1946 3
1947 1
1948 2
1950 1
1951 1
1952 6
1953 3
1954 1
1955 5
1956 5
1957 5
1958 3
1959 6
1960 2
1961 5
1962 5
1963 5
1964 2
1966 9
1967 5
1968 6
1969 13
1970 10
1971 8
1972 5
1973 6
1974 12
1975 15
1976 16
1977 20
1978 27
1979 26
1980 20
1981 24
1982 29
1983 31
1984 29
1985 31
1986 41
1987 38
1988 46
1989 68
1990 84
1991 80
1992 71
1993 80
1994 108
1995 111
1996 117
1997 139
1998 145
1999 139
2000 142
2001 141
2002 158
2003 163
2004 211
2005 210
2006 228
2007 258
2008 281
2009 311
2010 355
2011 409
2012 383
2013 452
2014 480
2015 491
2016 486
2017 529
2018 589
2019 595
2020 675
2021 663
2022 654
2023 440

Text availability

Article attribute

Article type

Publication date

Search Results

9,878 results

Results by year

Filters applied: . Clear all
Page 1
Nociceptor neurons affect cancer immunosurveillance.
Balood M, Ahmadi M, Eichwald T, Ahmadi A, Majdoubi A, Roversi K, Roversi K, Lucido CT, Restaino AC, Huang S, Ji L, Huang KC, Semerena E, Thomas SC, Trevino AE, Merrison H, Parrin A, Doyle B, Vermeer DW, Spanos WC, Williamson CS, Seehus CR, Foster SL, Dai H, Shu CJ, Rangachari M, Thibodeau J, V Del Rincon S, Drapkin R, Rafei M, Ghasemlou N, Vermeer PD, Woolf CJ, Talbot S. Balood M, et al. Among authors: thomas sc. Nature. 2022 Nov;611(7935):405-412. doi: 10.1038/s41586-022-05374-w. Epub 2022 Nov 2. Nature. 2022. PMID: 36323780 Free PMC article.
Calcium Modification in Percutaneous Coronary Interventions.
Shlofmitz RA, Galougahi KK, Jeremias A, Shlofmitz E, Thomas SV, Ali ZA. Shlofmitz RA, et al. Among authors: thomas sv. Interv Cardiol Clin. 2022 Oct;11(4):373-381. doi: 10.1016/j.iccl.2022.06.001. Epub 2022 Sep 15. Interv Cardiol Clin. 2022. PMID: 36243483 Review.
Biologics for dengue prevention: up-to-date.
Waickman AT, Newell K, Endy TP, Thomas SJ. Waickman AT, et al. Among authors: thomas sj. Expert Opin Biol Ther. 2023 Jan;23(1):73-87. doi: 10.1080/14712598.2022.2151837. Epub 2022 Dec 5. Expert Opin Biol Ther. 2023. PMID: 36417290 Review.
Medication Safety in Breastfeeding.
Spencer JP, Thomas S, Trondsen Pawlowski RH. Spencer JP, et al. Among authors: thomas s. Am Fam Physician. 2022 Dec;106(6):638-644. Am Fam Physician. 2022. PMID: 36521462
Reply.
Thomas SN, Stieglitz HM, Hackenmueller S, Suh-Lailam B, Pyle-Eilola AL. Thomas SN, et al. J Pediatr. 2023 Apr;255:260. doi: 10.1016/j.jpeds.2022.10.041. Epub 2022 Nov 16. J Pediatr. 2023. PMID: 36400240 No abstract available.
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
Winokur P, Gayed J, Fitz-Patrick D, Thomas SJ, Diya O, Lockhart S, Xu X, Zhang Y, Bangad V, Schwartz HI, Denham D, Cardona JF, Usdan L, Ginis J, Mensa FJ, Zou J, Xie X, Shi PY, Lu C, Buitrago S, Scully IL, Cooper D, Koury K, Jansen KU, Türeci Ö, Şahin U, Swanson KA, Gruber WC, Kitchin N; C4591031 Clinical Trial Group. Winokur P, et al. Among authors: thomas sj. N Engl J Med. 2023 Jan 19;388(3):214-227. doi: 10.1056/NEJMoa2213082. N Engl J Med. 2023. PMID: 36652353 Free PMC article. Clinical Trial.
Words Matter.
Benedetti DJ, Marron JM, Thomas SM, Caruso Brown AE, Pyke-Grimm KA, Johnson LM, Kodish E, Unguru Y. Benedetti DJ, et al. Among authors: thomas sm. J Clin Oncol. 2023 Jan 20;41(3):706-707. doi: 10.1200/JCO.22.01056. Epub 2022 Sep 23. J Clin Oncol. 2023. PMID: 36150097 No abstract available.
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Chesney J, et al. Among authors: thomas s. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755. J Immunother Cancer. 2022. PMID: 36600653 Free PMC article. Clinical Trial.
Reply by Authors.
Gill BC, Thomas S, Barden L, Jelovsek JE, Meyer I, Chermansky C, Komesu YM, Menefee S, Myers D, Smith A, Mazloomdoost D, Amundsen CL. Gill BC, et al. Among authors: thomas s. J Urol. 2023 Aug;210(2):340. doi: 10.1097/JU.0000000000003498.02. Epub 2023 May 22. J Urol. 2023. PMID: 37211805 No abstract available.
9,878 results